Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Enstilar Generic Name & Formulations
Legal Class
Rx
General Description
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.
Pharmacological Class
Vit. D3 derivative + topical steroid.
How Supplied
Foam—60g, 2x60g
Manufacturer
Enstilar Indications
Indications
Plaque psoriasis.
Enstilar Dosage and Administration
Adults and Children
<12yrs: not established. ≥12yrs: apply to affected areas once daily for up to 4 weeks; max 60g every 4 days. Discontinue when control is achieved. Do not occlude.
Enstilar Contraindications
Not Applicable
Enstilar Boxed Warnings
Not Applicable
Enstilar Warnings/Precautions
Warnings/Precautions
Avoid use near eyes, on face, groin, or axillae, or if atrophy is present at treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, or hyperglycemia occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Flammable. Allergic contact dermatitis. Pregnancy. Nursing mothers.
Enstilar Pharmacokinetics
See Literature
Enstilar Interactions
Interactions
Systemic absorption potentiated by other corticosteroids.
Enstilar Adverse Reactions
Adverse Reactions
Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.
Enstilar Clinical Trials
See Literature
Enstilar Note
Not Applicable
Enstilar Patient Counseling
See Literature
Images
